Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ribociclib with an Aromatase Inhibitor for Previously Untreated, HR-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, de Groot S, Riemsma R, Fayter D, Armstrong N, Portegijs P, Duffy S, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Pharmacoeconomics. 2019 Feb;37(2):141-153. doi: 10.1007/s40273-018-0708-4. Pharmacoeconomics. 2019. PMID: 30194622 Free PMC article. Review.
Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Büyükkaramikli NC, Blommestein HM, Riemsma R, Armstrong N, Clay FJ, Ross J, Worthy G, Severens J, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Pharmacoeconomics. 2017 Dec;35(12):1211-1221. doi: 10.1007/s40273-017-0528-y. Pharmacoeconomics. 2017. PMID: 28656543 Free PMC article. Review.
Pomalidomide with Dexamethasone for Treating Relapsed and Refractory Multiple Myeloma Previously Treated with Lenalidomide and Bortezomib: An Evidence Review Group Perspective of an NICE Single Technology Appraisal.
Büyükkaramikli NC, de Groot S, Fayter D, Wolff R, Armstrong N, Stirk L, Worthy G, Albuquerque de Almeida F, Kleijnen J, Al MJ. Büyükkaramikli NC, et al. Pharmacoeconomics. 2018 Feb;36(2):145-159. doi: 10.1007/s40273-017-0581-6. Pharmacoeconomics. 2018. PMID: 29086363 Free PMC article. Review.
Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW, Büyükkaramikli NC, Riemsma R, Fayter D, Armstrong N, Wei CY, Huertas Carrera V, Misso K, Worthy G, Kleijnen J, Corro Ramos I. Thielen FW, et al. Among authors: buyukkaramikli nc. Pharmacoeconomics. 2019 Aug;37(8):975-984. doi: 10.1007/s40273-018-0740-4. Pharmacoeconomics. 2019. PMID: 30547368 Free PMC article. Review.
Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.
Riemsma R, Corro Ramos I, Birnie R, Büyükkaramikli N, Armstrong N, Ryder S, Duffy S, Worthy G, Al M, Severens J, Kleijnen J. Riemsma R, et al. Health Technol Assess. 2016 Feb;20(17):v-xxxi, 1-251. doi: 10.3310/hta20170. Health Technol Assess. 2016. PMID: 26933827 Free PMC article. Review.
Avatrombopag and lusutrombopag for thrombocytopenia in people with chronic liver disease needing an elective procedure: a systematic review and cost-effectiveness analysis.
Armstrong N, Büyükkaramikli N, Penton H, Riemsma R, Wetzelaer P, Huertas Carrera V, Swift S, Drachen T, Raatz H, Ryder S, Shah D, Buksnys T, Worthy G, Duffy S, Al M, Kleijnen J. Armstrong N, et al. Health Technol Assess. 2020 Oct;24(51):1-220. doi: 10.3310/hta24510. Health Technol Assess. 2020. PMID: 33108266 Free PMC article.
EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties.
Dickson R, Boland A, Duarte R, Kotas E, Woolacott N, Hodgson R, Riemsma R, Grimm S, Ramaekers B, Joore M, Büyükkaramikli N, Kaltenthaler E, Stevenson M, Pandor A, Edwards S, Hoyle M, Shepherd J, Armoiry X, Brazzelli M. Dickson R, et al. Appl Health Econ Health Policy. 2018 Aug;16(4):429-432. doi: 10.1007/s40258-018-0393-7. Appl Health Econ Health Policy. 2018. PMID: 29808296 Free PMC article. No abstract available.
Severity-Adjusted Probability of Being Cost Effective.
Versteegh MM, Ramos IC, Buyukkaramikli NC, Ansaripour A, Reckers-Droog VT, Brouwer WBF. Versteegh MM, et al. Among authors: buyukkaramikli nc. Pharmacoeconomics. 2019 Sep;37(9):1155-1163. doi: 10.1007/s40273-019-00810-8. Pharmacoeconomics. 2019. PMID: 31134467 Free PMC article.
10 Years of End-of-Life Criteria in the United Kingdom.
Bovenberg J, Penton H, Buyukkaramikli N. Bovenberg J, et al. Value Health. 2021 May;24(5):691-698. doi: 10.1016/j.jval.2020.11.015. Epub 2021 Mar 20. Value Health. 2021. PMID: 33933238 Free article.
21 results